Channelopathies in pediatric neurology

Neurologic Clinics

Volumn 21, Issue 4, 2003, Pages 765-777

  Pandey, Hemant K ^a   Riggs, Jack E ^a,b  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BENZODIAZEPINE; CALCIUM CHANNEL; CARBAMAZEPINE; CHLORIDE CHANNEL; CHLORIDE CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; DIURETIC AGENT; GLYCINE RECEPTOR; ION CHANNEL; MEXILETINE; POTASSIUM CHANNEL; POTASSIUM CHLORIDE; QUINIDINE SULFATE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; THIAZIDE DIURETIC AGENT; TOCAINIDE;

ATAXIA; AUTOSOMAL DOMINANT DISORDER; CHILD; CHILDHOOD DISEASE; CONVULSION; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; EPILEPSY; FEBRILE CONVULSION; FRONTAL LOBE EPILEPSY; GENE MUTATION; HEMIPLEGIA; HEREDITARY HYPERREFLEXIA; HUMAN; HYPERREFLEXIA; HYPOKALEMIC PERIODIC PARALYSIS; MALIGNANT HYPERTHERMIA; MIGRAINE; MUSCLE BIOPSY; MYASTHENIA GRAVIS; MYOTONIA; NEUROLOGIC DISEASE; PERIODIC PARALYSIS; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; SPINOCEREBELLAR DEGENERATION; SYMPTOMATOLOGY; THOMSEN DISEASE;

EID: 0142043285     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(03)00012-4     Document Type: Review

References (67)

1. Griggs RC, Nutt JG. Episodic ataxias as channelopathies. Ann Neurol 1995;37:285-7.
2. Lorenz C, Meyer-Kleine C, Steinmeyer K, Koch MC, Jentsch TJ. Genomic organization of the human muscle chloride channel CIC-1 and analysis of novel mutations leading to Becker-type myotonia. Hum Mol Genet 1994;3:941-6.
3. Barchi RL. Ion channel mutations and diseases of skeletal muscle. Neurobiol Dis 1997;4:254-64.
4. Koch MC, Steinmeyer K, Lorenz C, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science 1992;257:797-800.
5. George AL Jr, Crackower MA, Abdalla JA, Hudson AJ, Ebers GC. Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita). Nat Genet 1993;3:305-10.
6. George AL Jr, Sloan-Brown K, Fenichel GM, Mitchell GA, Spiegel R, Pascuzzi RM. Nonsense and missense mutations of the muscle chloride channel gene in patients with myotonia congenita. Hum Mol Genet 1994;3:2071-2.
7. Becker PE. Genetic approaches to the nosology of muscular disease: myotonias and similar diseases. Birth Defects 1971;7:52-62.
8. George AL Jr. Hereditary dysfunction of voltage-gated sodium channels: from clinical phenotype to molecular mechanisms. Nephrol Dial Transplant 1996;11:1730-7.
9. Ptacek LJ, Tawil R, Griggs RC, et al. Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita and hyperkalemic periodic paralysis. Neurology 1994;44:1500-3.
10. Ptacek LJ, Trimmer JS, Agnew WS, Roberts JW, Petajan JH, Leppert M. Paramyotonia congenita and hyperkalemic periodic paralysis map to the same sodium-channel gene locus. Am J Hum Genet 1991;49:851-4.
11. Heine R, Pika U, Lehmann-Horn F. A novel SCN4A mutation causing myotonia aggravated by cold and potassium. Hum Mol Genet 1993;2:1349-53.
12. Ptacek LJ, Tyler F, Trimmer JS, Agnew WS, Leppert M. Analysis in a large hyperkalemic periodic paralysis pedigree supports tight linkage to a sodium channel locus. Am J Hum Genet 1991;49:378-82.
13. Fontaine B, Khurana TS, Hoffman EP, et al. Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene. Science 1990;250:1000-2.
14. Ptacek LJ, Tawil R, Griggs RC, Storvick D, Leppert M. Linkage of atypical myotonia congenita to a sodium channel locus. Neurology 1992;42:431-3.
15. Riggs JE. The periodic paralyses. Neurol Clin 1988;6:485-98.
16. Trudell RG, Kaiser KK, Griggs RC. Acetazolamide-responsive myotonia congenita. Neurology 1987;37:488-91.
17. Ricker K, Moxley RT, Heine R, Lehmann-Horn F. Myotonia fluctuans. A third type of muscle sodium channel disease. Arch Neurol 1994;51:1095-102.
18. Greenberg DA. Calcium channels in neurological disease. Ann Neurol 1997;42:275-82.
19. Buruma OJ, Bots GT, Went LN. Familial hypokalemic periodic paralysis. 50-year follow-up of a large family. Arch Neurol 1985;42:28-31.
20. Links TP, Smit AJ, Molenaar WM, Zwarts MJ, Oosterhuis HJ. Familial hypokalemic periodic paralysis. Clinical, diagnostic and therapeutic aspects. J Neurol Sci 1994;122:33-43.
21. Fontaine B, Vale-Santos J, Jurkat-Rott K, et al. Mapping of hypokalaemic periodic paralysis (HypoPP) locus to chromosome 1q31-32 in three European families. Nat Genet 1994;6:267-72.
22. Ptacek LJ, Tawil R, Griggs RC, et al. Dihydropyridine receptor mutations cause hypokalaemic periodic paralysis. Cell 1994;77:863-8.
23. Quane KA, Healy JM, Keating KE, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993;5:51-5.
24. Fujii J, Otsu K, Zorzato F, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991;253:448-51.
25. Gommans IM, Vlak MH, de Haan A, van Engelen BG. Calcium regulation and muscle disease. J Muscle Res Cell Motil 2002;23:59-63.
26. Robinson RL, Brooks C, Brown SL, et al. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum Mutat 2002;20:88-97.
27. Sewry CA, Muller C, Davis M, et al. The spectrum of pathology in central core disease. Neuromuscul Disord 2002;12:930-8.
28. Jan LY, Jan YN. Cloned potassium channels from eukaryotes and prokaryotes. Annu Rev Neurosci 1997;20:91-123.
29. Beckh S, Pongs O. Members of the RCK potassium channel family are differentially expressed in the rat nervous system. EMBO J 1990;9:777-82.
30. Brunt ER, van Weerden TW. Familial paroxysmal kinesigenic ataxia and continuous myokymia. Brain 1990;113:1361-82.
31. Litt M, Kramer P, Browne D, et al. A gene for episodic ataxia/myokymia maps to chromosome 12p13. Am J Hum Genet 1994;55:702-9.
32. Eunson LH, Rea R, Zuberi SM, et al. Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol 2000;48:647-56.
33. Ronen GM, Rosales TO, Connolly M, Anderson VE, Leppert M. Seizure characteristics in chromosome 20 benign familial neonatal convulsions. Neurology 1993;43:1355-60.
34. Lewis TB, Leach RJ, Ward K, O'Connell P, Ryan SG. Genetic heterogeneity in benign familial neonatal convulsions: identification of a new locus on chromosome 8q. Am J Hum Genet 1993;53:670-5.
35. Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998;18:25-9.
36. Charlier C, Singh NA, Ryan SG, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 1998;18:53-5.
37. 2+ channel gene CACNL1A4. Cell 1996;87:543-52.
38. Elliott MA, Peroutka SJ, Welch S, May EF. Familial hemiplegic migraine, nystagmus, and cerebellar atrophy. Ann Neurol 1996;39:100-6.
39. Vahedi K, Joutel A, Van Bogaert P, et al. A gene for cerebellar paroxysmal ataxia maps to chromosome 19p. Ann Neurol 1995;37:289-93.
40. von Brederlow B, Hahn AF, Koopman WJ, Ebers GC, Bulman DE. Mapping the gene for acetazolamide responsive hereditary paroxysmal cerebellar ataxia to chromosome 19p. Hum Mol Genet 1995;4:279-84.
41. Teh BT, Silburn P, Lindblad K, et al. Familial periodic cerebellar ataxia without myokymia maps to a 19-cM region on 19p13. Am J Hum Genet 1995;56:1443-9.
42. Baloh RW, Yue Q, Furman JM, Nelson SF. Familial episodic ataxia: clinical heterogeneity in four families linked to chromosome 19p. Ann Neurol 1997;41:8-16.
43. Zhuchenko O, Bailey J, Bonnen P, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the 1A-voltage-dependent calcium channel. Nat Genet 1997;15:62-9.
44. Jodice C, Mantuano E, Venziano L, et al. Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. Hum Mol Genet 1997;6:1973-8.
45. Riess O, Schols L, Bottger H, et al. SCA6 is caused by moderate CAG expansion in the alpha] A-voltage-dependent calcium channel gene. Hum Mol Genet 1997;6:1289-93.
46. Zhuchenko O, Bailey J, Bonnen P, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 1997;15:62-9.
47. Skinner PJ, Koshy BT, Cummings CJ, et al. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 1997;389:971-4.
48. Novakovic SD, Eglen RM, Hunter JC. Regulation of Na + channel distribution in the nervous system. Trends Neurosci 2001;24:473-8.
49. Catterall WA. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv Neurol 1999;79:441-56.
50. Wallace RH, Scheffer IE, Parasivam G, et al. Generalized epilepsy with febrile seizures plus: mutation of the sodium channel subunit SCN1B. Neurology 2002;58:1426-9.
51. Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. Brain 1997;120:479-90.
52. Singh R, Scheffer IE, Crossland K, Berkovic SF. Generalized epilepsy with febrile seizures plus: a common childhood-onset genetic epilepsy syndrome. Ann Neurol 1999;45:75-81.
53. Ptacek LJ. Ligand-gated ion channelopathies: mutations in different genes causing one disease. Neurology 2000;55:1429-30.
54. Scheffer IE, Bhatia KP, Lopes-Cendes I, et al. Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet 1994;343:515-7.
55. Scheffer IE, Bhatia KP, Lopes-Cendes I, et al. Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain 1995;118:61-73.
56. Phillips HA, Scheffer IE, Berkovic SF, Hollway GE, Sutherland GR, Mulley JC. Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q 13.2. Nat Genet 1995;10:117-8.
57. Steinlein OK, Mulley JC, Propping P, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995;11:201-3.
58. Ohno K, Engel AG. Congenital myasthenic syndromes: genetic defects of the neuromuscular junction. Curr Neurol Neurosci Rep 2002;2:78-88.
59. Harper CM, Engel AG. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann Neurol 1998;43:480-4.
60. Gomez CM, Maselli RA, Vohra BP, et al. Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms. Ann Neurol 2002;51:102-12.
61. Ohno K, Engel AG, Shen XM, et al. Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome. Am J Hum Genet 2002;70:875-85.
62. Abicht A, Stucka R, Schmidt C, et al. A newly identified chromosomal microdeletion and an N-box mutation of the AChR epsilon gene cause a congenital myasthenic syndrome. Brain 2002;125:1005-13.
63. Shen XM, Ohno K, Fukudome T, et al. Congenital myasthenic syndrome caused by low-expressor fast-channel AChR delta subunit mutation. Neurology 2002;59:1881-2.
64. Shiang R, Ryan SG, Zhu YZ, Hahn AF, O'Connell P, Wasmuth JJ. Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurological disorder, hyperekplexia. Nat Genet 1993;5:351-8.
65. Zhou L, Chillag KL, Nigro MA. Hyperekplexia: a treatable neurogenetic disease. Brain Dev 2002;24:669-74.
66. Tijssen MA, Vergouwe MN, van Dijk JG, Rees M, Frants RR, Brown P. Major and minor form of hereditary hyperekplexia. Mov Disord 2002;17:826-30.
67. Ryan SG, Sherman SL, Terry JC, Sparkes RS, Torres MC, Mackey RW. Startle disease, or hyperekplexia: response to clonazepam and assignment of the gene (STHE) to chromosome 5q by linkage analysis. Ann Neurol 1992;31:663-8.